Despite 20 years of research and new treatment methods, diabetic foot ulcer (DFU) remains a common problem with frequent recurrences and complications. There are reports that nerve decompression (ND) surgery has been observed to produce significantly fewer DFU recurrences than standard of care (SOC). The explanation of this apparent superiority has not been understood. Microcirculation is understood to be involved in diabetic peripheral neuropathy (DPN) and DFU. There is an underappreciation of the participation in DPN of entrapment neuropathy (EN) due to nerve swelling and impingement in fibro-osseous tunnels. Reducing c-fiber compression in EN by ND generates recovery of subepidermal capillary flow. ND studies have found improved neuromuscular function and epidermal microcirculation phenomena, including chronic capillary ischemia (CCI) and pressure-induced vasodilatation (PIV). There is no current therapy recommended for impaired microcirculation. Clinical and animal evidence has demonstrated that release of locally compressed peripheral nerves improves the epidermal microcirculation which is under sympathetic control. Using epineurolysis to relieve nerve compressions is a physiology-based therapeutic intervention and provides the scientific foundation clarifying how ND reduces DFU recurrence risk. Incorporating ND with current SOC treatments could improve DFU recurrence risk, hard-to-heal ulcers, neuroischemic wounds, amputation risk, and the resulting costs to society. More studies using ND for DFU, especially evidence-based medicine Level I studies, are needed to confirm these preliminary outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/wound.2023.0199 | DOI Listing |
Ther Adv Endocrinol Metab
November 2024
Aurealis Therapeutics, Microkatu 1, Kuopio 70210, Finland.
Background: Diabetic foot ulcer (DFU) is a common and highly morbid complication of diabetes with high unmet medical needs. AUP1602-C, a topical four-in-one gene therapy medicinal product (GTMP), consisting of a strain that produces fibroblast growth factor-2, interleukin-4, and colony-stimulating factor-1, is a promising novel treatment for DFU.
Objectives: The aim of this first-in-human study was to investigate whether AUP1602-C is safe and effective in improving wound healing and quality of life (QoL) in patients with non-healing DFU (nhDFU), and to determine the recommended phase II dose.
Sci Rep
January 2025
Department of Endocrinology, NRS Medical College and Hospital, Kolkata, West Bengal, India.
Professionals like deep-miners and factory-workers wear specialized safety-shoes to protect against occupational hazards (OF). The risk factors, clinico-microbiologic profile and complications of diabetic foot ulcers (DFU) in these professionals remain unexplored. A cross-sectional observational study was conducted to describe the unique clinico-microbiologic profile of DFU in those wearing occupational-footwear (OF) and find risk factors for DFU related osteomyelitis in them.
View Article and Find Full Text PDFWorld J Diabetes
January 2025
Department of Nephrology, Zhejiang Provincial People's Hospital Bijie Hospital, Bijie 551700, Guizhou Province, China.
Diabetic foot ulcers (DFUs) represents a significant public health issue, with a rising global prevalence and severe potential complications including amputation. Traditional treatments often fall short due to various limitations such as high recurrence rates and extensive resource utilization. This editorial explores the innovative use of acellular fish skin grafts as a transformative approach in DFU management.
View Article and Find Full Text PDFFront Med (Lausanne)
December 2024
Department of Clinical Laboratory, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.
Curr Diabetes Rev
December 2024
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Diabetic Foot Ulcer (DFU) is a major complication of diabetes that mostly affects the lower extremities, with a high incidence and recurrence rate in approximately 15% of patients with diabetes. The complexity of diabetic wounds poses a substantial challenge for clinical recovery, underscoring the need to investigate novel therapeutic approaches. Medicinal plants have been used to treat ulcers for centuries.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!